{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:02Z","timestamp":1787768582941,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>High-dose chemotherapy with melphalan, followed by autologous hematopoietic stem cell transplantation (AHCT) remains the standard of care for consolidation therapy of fit patients with newly diagnosed multiple myeloma (NDMM), for more than 20 years now.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective study of NDMM patients who underwent AHCT at our center from 2011 to 2018. Data was undertaken using the hospital electronic medical records (EMR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among transplant eligible patients (which were 764), 78 patients (10.2%) underwent AHCT. The predominant stage in the study cohort was International Scoring System (ISS)-III (55%), and IgG-kappa (44%) was the commonest subtype of multiple myeloma (MM). Light chain myeloma was found in 23.5% of patients. Pretransplant, 42%, 48%, and 10% patients were in more than very good partial response (&gt;VGPR), very good partial response (VGPR), and partial response (PR), respectively. The median duration of follow-up was 57.2 months (range: 12.1\u2013120.2 months). The entire cohort\u2019s 5-year overall survival (OS) and progression-free survival (PFS) were 89.1% and 41.8%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bortezomib based triplet induction regimens were effective and well tolerated in this retrospective analysis of Indian patients. We observed that AHCT effectively achieves deep and durable remission in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_78_22","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T08:01:24Z","timestamp":1705996884000},"page":"486-492","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature"],"prefix":"10.4103","volume":"60","author":[{"given":"Manthan","family":"Kathrotiya","sequence":"first","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh J.","family":"Bhave","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Nag","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Arora","sequence":"additional","affiliation":[{"name":"Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Roychoudhry","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology and HCT, Nursing Division, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Parihar","sequence":"additional","affiliation":[{"name":"Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Mishra","sequence":"additional","affiliation":[{"name":"Laboratory Hematology and Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Nair","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mammen","family":"Chandy","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5230-1214","authenticated-orcid":false,"given":"Jeevan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Departments of Clinical Hematology and HCT, Tata Medical Center, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet Lond Engl"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2017-05-693606","article-title":"How I treat the young patient with multiple myeloma","volume":"132","author":"Gandolfi","year":"2018","journal-title":"Blood"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: Impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ejh.12890","article-title":"Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning","volume":"99","author":"Munker","year":"2017","journal-title":"Eur J Haematol"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ejh.12869","article-title":"Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma","volume":"98","author":"Gassiot","year":"2017","journal-title":"Eur J Haematol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12288-019-01111-y","article-title":"Stem cell transplantation in multiple myeloma: Very much alive and kicking","volume":"35","author":"Yanamandra","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"106167","DOI":"10.1016\/j.leukres.2019.106167","article-title":"Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: Lesson from a Tertiary Cancer Centre in rural India","volume":"83","author":"Nair","year":"2019","journal-title":"Leuk Res"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00277-018-3370-1","article-title":"Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma","volume":"97","author":"Aggarwal","year":"2018","journal-title":"Ann Hematol"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2020.08.021","article-title":"Multiple myeloma-effect of induction therapy on transplant outcomes","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12288-017-0876-y","article-title":"Autologous stem cell transplantation for multiple myeloma: Single centre experience from North India","volume":"34","author":"Malhotra","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary results from the randomized phase iII trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial)","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bbmt.2020.04.016","article-title":"Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies?A review from the chronic malignancies working party of the EBMT","volume":"26","author":"Garderet","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15_suppl","key":"R26-20240828","first-page":"8000","article-title":"Upfront Autologous stem cell transplantation (ASCT) versus novel agent-based therapy for Multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial)","volume":"34","author":"Sonneveld","year":"2018","journal-title":"J Clin Oncol"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12288-018-0989-y","article-title":"Clinical outcomes in multiple myeloma post-autologous transplantation-A single centre experience","volume":"35","author":"Kulkarni","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","article-title":"Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"78","author":"Klaus","year":"2007","journal-title":"Eur J Haematol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_78_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:15:43Z","timestamp":1787768143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_78_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_78_22","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2022-01-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}